David Gentien

7.1k total citations
83 papers, 2.7k citations indexed

About

David Gentien is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, David Gentien has authored 83 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Molecular Biology, 35 papers in Oncology and 35 papers in Cancer Research. Recurrent topics in David Gentien's work include Cancer Genomics and Diagnostics (25 papers), Cancer Cells and Metastasis (13 papers) and Breast Cancer Treatment Studies (10 papers). David Gentien is often cited by papers focused on Cancer Genomics and Diagnostics (25 papers), Cancer Cells and Metastasis (13 papers) and Breast Cancer Treatment Studies (10 papers). David Gentien collaborates with scholars based in France, United States and Germany. David Gentien's co-authors include Sergio Roman‐Roman, Audrey Rapinat, Pierre de la Grange, Marc‐Henri Stern, Sophie Piperno‐Neumann, Laurence Desjardins, Anne Vincent‐Salomon, Didier Decaudin, Amaury G. Dumont and Malin Pedersen and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Nature Genetics.

In The Last Decade

David Gentien

80 papers receiving 2.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Gentien France 29 1.4k 902 868 484 334 83 2.7k
Vladimir Bezrookove United States 28 2.1k 1.5× 1.0k 1.1× 724 0.8× 225 0.5× 613 1.8× 48 3.3k
Ellen van Drunen Netherlands 27 2.5k 1.8× 960 1.1× 541 0.6× 259 0.5× 189 0.6× 42 3.7k
David MacPherson United States 31 2.7k 1.9× 2.4k 2.7× 693 0.8× 498 1.0× 289 0.9× 48 4.3k
Malin Pedersen United Kingdom 22 1.3k 0.9× 1.1k 1.2× 293 0.3× 267 0.6× 164 0.5× 37 2.4k
Jan J. Molenaar Netherlands 32 1.8k 1.3× 894 1.0× 932 1.1× 296 0.6× 62 0.2× 91 3.2k
A. Hunter Shain United States 23 2.8k 2.0× 2.1k 2.3× 1.2k 1.4× 571 1.2× 255 0.8× 36 4.6k
Karen Fink United States 31 1.6k 1.1× 796 0.9× 1.1k 1.3× 1.4k 2.9× 134 0.4× 73 4.7k
David W. Goodrich United States 34 3.1k 2.2× 2.3k 2.5× 788 0.9× 1.1k 2.4× 394 1.2× 97 5.0k
Pamela M. Pollock Australia 34 2.6k 1.8× 1.3k 1.5× 884 1.0× 402 0.8× 56 0.2× 90 4.0k
Charles Decraene France 22 645 0.5× 596 0.7× 571 0.7× 251 0.5× 78 0.2× 40 1.4k

Countries citing papers authored by David Gentien

Since Specialization
Citations

This map shows the geographic impact of David Gentien's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Gentien with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Gentien more than expected).

Fields of papers citing papers by David Gentien

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Gentien. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Gentien. The network helps show where David Gentien may publish in the future.

Co-authorship network of co-authors of David Gentien

This figure shows the co-authorship network connecting the top 25 collaborators of David Gentien. A scholar is included among the top collaborators of David Gentien based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Gentien. David Gentien is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Botty, Rania El, Sophie Vacher, Adrien Briaux, et al.. (2023). HORMAD1 overexpression predicts response to anthracycline–cyclophosphamide and survival in triple‐negative breast cancers. Molecular Oncology. 17(10). 2017–2028. 5 indexed citations
2.
Zeng, Qinghe, Christophe Klein, Stefano Caruso, et al.. (2022). Artificial intelligence predicts immune and inflammatory gene signatures directly from hepatocellular carcinoma histology. Journal of Hepatology. 77(1). 116–127. 72 indexed citations
3.
Marisa, Laëtitia, Yuna Blum, Julien Taı̈eb, et al.. (2021). Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer. Clinical Cancer Research. 27(17). 4768–4780. 37 indexed citations
4.
5.
Cros, Jérôme, Nathalie Théou–Anton, V. Gounant, et al.. (2020). Specific Genomic Alterations in High-Grade Pulmonary Neuroendocrine Tumours with Carcinoid Morphology. Neuroendocrinology. 111(1-2). 158–169. 32 indexed citations
6.
Bemmel, Joke G. van, Rafael Galupa, Nicolas Servant, et al.. (2019). The bipartite TAD organization of the X-inactivation center ensures opposing developmental regulation of Tsix and Xist. Nature Genetics. 51(6). 1024–1034. 55 indexed citations
7.
Assayag, Franck, Florian Bonin, Sophie Château‐Joubert, et al.. (2018). The iron chelator deferasirox synergises with chemotherapy to treat triple‐negative breast cancers. The Journal of Pathology. 246(1). 103–114. 53 indexed citations
8.
Lecler, Augustin, Christine Lévy‐Gabriel, C. Reyes, et al.. (2017). Evisceration and ocular tumors: What are the consequences?. Journal Français d Ophtalmologie. 40(2). 93–101. 5 indexed citations
9.
Rouzier, Roman, et al.. (2017). Denaturing fixatives are compatible with the NanoString nCounter® platform and the Prosigna® assay. New Biotechnology. 36. 37–41. 1 indexed citations
10.
Gurard‐Levin, Zachary A., Natalie A. Twine, Véra Pancaldi, et al.. (2016). Chromatin Regulators as a Guide for Cancer Treatment Choice. Molecular Cancer Therapeutics. 15(7). 1768–1777. 15 indexed citations
11.
Massonnet, Gérald, David Gentien, Zofia Maciorowski, et al.. (2016). Characterization of Breast Cancer Preclinical Models Reveals a Specific Pattern of Macrophage Polarization. PLoS ONE. 11(7). e0157670–e0157670. 9 indexed citations
12.
Cottu, Paul, Ivan Bièche, Franck Assayag, et al.. (2014). Acquired Resistance to Endocrine Treatments Is Associated with Tumor-Specific Molecular Changes in Patient-Derived Luminal Breast Cancer Xenografts. Clinical Cancer Research. 20(16). 4314–4325. 42 indexed citations
13.
McGuire, John R., Morgane Sonia Thion, David Gentien, et al.. (2013). The Huntington disease protein accelerates breast tumour development and metastasis through ErbB2/HER2 signalling. EMBO Molecular Medicine. 5(2). 309–325. 29 indexed citations
14.
15.
Maire, Virginie, Céline Baldeyron, Marion Richardson, et al.. (2013). TTK/hMPS1 Is an Attractive Therapeutic Target for Triple-Negative Breast Cancer. PLoS ONE. 8(5). e63712–e63712. 119 indexed citations
16.
17.
Vincent‐Salomon, Anne, Vanessa Benhamo, Eléonore Gravier, et al.. (2013). Genomic Instability: A Stronger Prognostic Marker Than Proliferation for Early Stage Luminal Breast Carcinomas. PLoS ONE. 8(10). e76496–e76496. 14 indexed citations
18.
Madic, Jordan, Sophie Piperno‐Neumann, Vincent Servois, et al.. (2012). Pyrophosphorolysis-Activated Polymerization Detects Circulating Tumor DNA in Metastatic Uveal Melanoma. Clinical Cancer Research. 18(14). 3934–3941. 65 indexed citations
19.
Reyal, Fabien, Charlotte Guyader, Charles Decraene, et al.. (2012). Molecular profiling of patient-derived breast cancer xenografts. Breast Cancer Research. 14(1). R11–R11. 140 indexed citations
20.
Billottet, Clotilde, Marianne Tuefferd, David Gentien, et al.. (2008). Modulation of several waves of gene expression during FGF‐1 induced epithelial‐mesenchymal transition of carcinoma cells. Journal of Cellular Biochemistry. 104(3). 826–839. 45 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Vladimir Bezrookove Breakdown of academic impact, for papers by Ellen van Drunen Breakdown of academic impact, for papers by David MacPherson Breakdown of academic impact, for papers by Malin Pedersen Breakdown of academic impact, for papers by Jan J. Molenaar Breakdown of academic impact, for papers by A. Hunter Shain Breakdown of academic impact, for papers by Karen Fink Breakdown of academic impact, for papers by David W. Goodrich Breakdown of academic impact, for papers by Pamela M. Pollock Breakdown of academic impact, for papers by Charles Decraene
Rankless by CCL
2026